| scholarly article | Q13442814 |
| P356 | DOI | 10.4161/HV.18865 |
| P698 | PubMed publication ID | 22327492 |
| P2093 | author name string | Toufik Zahaf | |
| Dominique Descamps | |||
| Brecht Geeraerts | |||
| Paulo Naud | |||
| Julio C Teixeira | |||
| Cecilia M Roteli-Martins | |||
| Nervo Sanchez | |||
| Newton S De Carvalho | |||
| Paola De Borba | |||
| P433 | issue | 3 | |
| P304 | page(s) | 390-397 | |
| P577 | publication date | 2012-02-13 | |
| P1433 | published in | Human Vaccines & Immunotherapeutics | Q21072749 |
| P1476 | title | Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up | |
| P478 | volume | 8 |
| Q35724932 | A cost-utility analysis of cervical cancer screening and human papillomavirus vaccination in the Philippines |
| Q36259403 | A review of clinical trials of human papillomavirus prophylactic vaccines |
| Q42229390 | A three component mix of thioredoxin-L2 antigens elicits broadly neutralizing responses against oncogenic human papillomaviruses |
| Q37202927 | A universal virus-like particle-based vaccine for human papillomavirus: longevity of protection and role of endogenous and exogenous adjuvants |
| Q44408279 | Adherence to cervical screening in the era of human papillomavirus vaccination: how low is too low? |
| Q35013844 | Age-specific occurrence of HPV16- and HPV18-related cervical cancer |
| Q34102466 | Alternative dosage schedules with HPV virus-like particle vaccines |
| Q34695768 | An epidemiological study assessing the prevalence of human papillomavirus types in women in the Kingdom of Bahrain. |
| Q36952972 | Answering human papillomavirus vaccine concerns; a matter of science and time |
| Q26783973 | Are the Two Human Papillomavirus Vaccines Really Similar? A Systematic Review of Available Evidence: Efficacy of the Two Vaccines against HPV |
| Q26851311 | Cervical Cancer |
| Q37943650 | Cervical adenocarcinoma: moving towards better prevention |
| Q40432574 | Cervical cancer screening in women vaccinated against human papillomavirus infection: Recommendations from a consensus conference |
| Q34994905 | Characteristics of HPV-specific antibody responses induced by infection and vaccination: cross-reactivity, neutralizing activity, avidity and IgG subclasses |
| Q38111962 | Clinical trials of human papillomavirus vaccines and beyond |
| Q35886534 | Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase III randomized trial |
| Q58120027 | Correlates of GLA family adjuvants' activities |
| Q34475547 | Costs of delivering human papillomavirus vaccination to schoolgirls in Mwanza Region, Tanzania |
| Q26991640 | Current status of human papillomavirus vaccines |
| Q41269236 | Development of chimeric candidate vaccine against HPV18: a proof of concept. |
| Q37709718 | Does the HPV vaccination programme have implications for cervical screening programmes in the UK? |
| Q42257816 | Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial |
| Q54291238 | Effect of HPV vaccination and cervical cancer screening in England by ethnicity: a modelling study. |
| Q64086046 | Effect of Multiple Vaccinations with Tumor Cell-Based Vaccine with Codon-Modified GM-CSF on Tumor Growth in a Mouse Model |
| Q64070233 | Effect of an educational intervention on HPV knowledge and attitudes towards HPV and its vaccines among junior middle school students in Chengdu, China |
| Q41051528 | Effectiveness of human papillomavirus vaccine against incident and persistent infections among young girls: Results from a longitudinal Dutch cohort study |
| Q34199560 | Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial |
| Q34291189 | Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women. |
| Q37609451 | Efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine in Chinese women aged 18-25 years: event-triggered analysis of a randomized controlled trial. |
| Q50709977 | Eliciting youth and adult recommendations through citizens' juries to improve school based adolescent immunisation programs. |
| Q56967486 | Emerging human papillomavirus vaccines |
| Q37735000 | Enhancement of humoral and cell mediated immune response to HPV16 L1-derived peptides subsequent to vaccination with prophylactic bivalent HPV L1 virus-like particle vaccine in healthy females |
| Q90219737 | Epidemiology of Head and Neck Squamous Cell Carcinomas: Impact on Staging and Prevention Strategies |
| Q39447224 | Estimating the long-term effects of HPV vaccination in Germany |
| Q30251868 | Eurogin Roadmap 2015: How has HPV knowledge changed our practice: Vaccines |
| Q97565439 | Evidence of HPV vaccination efficacy comes from more than clinical trials |
| Q47554977 | Explanations for the high potency of HPV prophylactic vaccines |
| Q37619140 | From discovery to licensure, the Adjuvant System story |
| Q84738611 | Girls' preferences for HPV vaccination: a discrete choice experiment |
| Q35950913 | HPV Serology Testing Confirms High HPV Immunisation Coverage in England |
| Q34157209 | HPV catch-up vaccination of young women: a systematic review and meta-analysis |
| Q35887782 | HPV vaccination for prevention of skin cancer |
| Q37654047 | HPV vaccination in India |
| Q38112976 | HPV vaccine cross-protection: Highlights on additional clinical benefit. |
| Q38194254 | HPV vaccines to prevent cervical cancer and genital warts: an update |
| Q37134978 | HPV vaccines: Translating immunogenicity into efficacy |
| Q34066068 | Have preferences of girls changed almost 3 years after the much debated start of the HPV vaccination program in The Netherlands? A discrete choice experiment |
| Q60486415 | Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine (Cervarix®): A Guide to Its Two-Dose Schedule in Girls Aged 9–14 Years in the EU |
| Q34746772 | Human papillomavirus prevalence and type distribution among women attending routine gynecological examinations in Saudi Arabia. |
| Q42256696 | Human papillomavirus vaccination and Pap testing profile in Manitoba, Canada |
| Q26853556 | Human papillomavirus vaccination: a case study in translational science |
| Q36977720 | Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study |
| Q34291136 | Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years. |
| Q47549756 | Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development |
| Q38861345 | Immunogenicity of bivalent HPV vaccine among partially vaccinated young adolescent girls in Uganda |
| Q33929216 | Impact of smoking on the quantity and quality of antibodies induced by human papillomavirus type 16 and 18 AS04-adjuvanted virus-like-particle vaccine - a pilot study |
| Q33682928 | Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types |
| Q40299388 | Introduction of molecular HPV testing as the primary technology in cervical cancer screening: Acting on evidence to change the current paradigm |
| Q37467149 | Is human papillomavirus vaccination likely to be a useful strategy in India? |
| Q37425284 | Literature review of vaccine-related adverse events reported from HPV vaccination in randomized controlled trials |
| Q28081156 | Long-term efficacy and safety of human papillomavirus vaccination |
| Q97526303 | Measuring vaccine effectiveness against persistent HPV infections: a comparison of different statistical approaches |
| Q42204836 | Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes |
| Q33719736 | Parents' preferences for vaccinating daughters against human papillomavirus in the Netherlands: a discrete choice experiment |
| Q35810353 | Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15-55 years and first-time modelling of antibody responses in mature women: results from an open-label 6-year follow-up study |
| Q30780649 | Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme |
| Q92658758 | Preclinical study of safety and immunogenicity of combined rubella and human papillomavirus vaccines: Towards enhancing vaccination uptake rates in developing countries |
| Q33759930 | Prospects for prevention of HPV-driven oropharynx cancer |
| Q35452705 | Raising expectations for subunit vaccine |
| Q30300329 | Rationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa Rica |
| Q33953881 | Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA. |
| Q36796538 | Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine: a randomized trial in 10-25-year-old HIV-Seronegative African girls and young women |
| Q35541886 | Second-generation prophylactic HPV vaccines: successes and challenges |
| Q36978409 | Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination |
| Q36671106 | The challenge of developing a herpes simplex virus 2 vaccine |
| Q30251408 | The potential impact of prophylactic human papillomavirus vaccination on oropharyngeal cancer |
| Q37719631 | The road ahead for cervical cancer prevention and control |
| Q38041983 | Understanding and learning from the success of prophylactic human papillomavirus vaccines. |
| Q30843312 | Utilization of administrative data to assess the association of an adolescent health check-up with human papillomavirus vaccine uptake in Germany. |
| Q34806423 | Vaccinating Girls and Boys with Different Human Papillomavirus Vaccines: Can It Optimise Population-Level Effectiveness? |
| Q38971587 | Vaccination Expectations in HNSCC. |
| Q26783879 | Vaccine Adjuvants: from 1920 to 2015 and Beyond |
| Q35826767 | Vaccine Potentiation by Combination Adjuvants |
Search more.